Tego Biosciences

Tego Biosciences is a preclinical-stage biotechnology company dedicated to overcoming the blood-brain barrier (BBB) to treat central nervous system (CNS) disorders. The company utilizes a proprietary platform designed to facilitate the transport of large molecule biologics, such as antibodies and enzymes, into the brain via receptor-mediated transcytosis. By enabling effective delivery of therapeutic payloads, Tego aims to address high-need areas including neurodegenerative diseases and lysosomal storage disorders. The leadership team includes veterans from the pharmaceutical industry with extensive experience in CNS drug discovery and development. The company's innovative approach seeks to unlock the therapeutic potential of biologics for patients suffering from debilitating brain conditions.